Calithera Biosciences Quote - CALA | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Calithera Biosciences Inc (CALA) Share Price

Calithera Biosciences Inc (CALA)

0.20

0.00

(0.00%)

At close: 05 November 8:00AM

Delayed by 15 minutes

0.20

0.00

( 0.00% )

After Hours: -

Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Current Price

0.20

Bid

0.16

Offer

0.35

Volume

-

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

Previous Close

0.20

Open

-

Last Trade

Last Trade Time

-

Financial Volume

-

VWAP

-

Average Volume (3m)

-

Shares Outstanding

4,872,497

Dividend Yield

-

PE Ratio

-0.05

Earnings Per Share (EPS)

-4.37

Revenue

-

Net Profit

-21.29M

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumo... Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.calithera.com

Headquarters

Wilmington, Delaware, USA

Founded

-

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: “CALA”). Calithera Biosciences, Inc. (the “Company”) announced that it was unable to achieve a...

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: CALA) (the “Company”) announced that it intends to hold a special meeting of stockholders on or...

Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive...

Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...

Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced...

Calithera Biosciences Gets FDA Fast Track For Lung Cancer Drug

By Will Feuer Calithera Biosciences Inc. said the U.S. Food and Drug Administration has granted fast-track designation for the company's investigational treatment for adults with unresectable...

Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that...

Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that...

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...

Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
IDAIT Stamp Inc	US$ 0.3636 (49.26%)	7.54M
PTIRGraniteShares 2X Long PLTR Daily ETF	US$ 55.29 (26.55%)	39.94k
ALABAstera Labs Inc	US$ 82.90 (19.16%)	165.52k
BREABrera Holdings PLC	US$ 1.05 (17.98%)	1.28M
CLEUChina Liberal Education Holdings Ltd	US$ 0.2699 (16.84%)	31.79k
MQMarqeta Inc	US$ 4.39 (-26.34%)	228.33k
PRPLPurple Innovation Inc	US$ 0.79 (-15.96%)	71.76k
MYNZMainz BioMed NV	US$ 0.2159 (-10.79%)	4.65k
ABCLAbCellera Biologics Inc	US$ 2.598 (-9.79%)	57.96k
CRUSCirrus Logic Inc	US$ 100.00 (-9.68%)	24.82k
IDAIT Stamp Inc	US$ 0.3621 (48.65%)	7.54M
NVDANVIDIA Corporation	US$ 136.49 (0.29%)	2.98M
ELABElevai Labs Inc	US$ 0.0208 (2.97%)	2.18M
PTONPeloton Interactive Inc	US$ 7.51 (0.13%)	2.04M
ACADAcadia Pharmaceuticals Inc	US$ 14.62 (0.00%)	1.52M

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2 years ago

maybe soon will see something

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2 years ago

maybe soon will see something

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2 years ago

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2 years ago

cala soon something

Renee

Renee 2 years ago

CALA delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

kzivann

kzivann 2 years ago

CALA dissolving. https://quantisnow.com/insight/3950020

Mr. Zen

Mr. Zen 2 years ago

Calithera continued to advance multiple vacuolar protein sorting-associated protein 4A (VPS4A) and VPS4B inhibitors through lead optimization and plans to share updates on this program by the end of 2022.

Nealio

Nealio 2 years ago

CALA - continues upward. 100% gain in last month, very good swing play. Drug data was good...float is very low at 4.X M shares.

Nealio

Nealio 2 years ago

CALA in play! Drug data and earnings report. Should move even higher on this news.

Nealio

Nealio 2 years ago

Chart looks very good atm.

Nealio

Nealio 2 years ago

Could be the start of a big run; or not. We shall see; with recent good news, I like the chances. Good luck to all!

ttottip

ttottip 2 years ago

ttottip

ttottip 2 years ago

Good morning all! Hoping for a reversal today.

ttottip

ttottip 2 years ago

I'm not hesitating to buy at these levels!

bandit007

bandit007 3 years ago

Took a few here. $CALA

kzivann

kzivann 3 years ago

Moving after hours.

CALA

crudeoil24

crudeoil24 3 years ago

Calithera Biosciences shares are trading higher after Ladenburg Thalmann initiated coverage on the stock with a Buy rating and a $4 price target.

CALA

TheFinalCD

TheFinalCD 3 years ago

big move 45-74

$CALA

glens0

glens0 3 years ago

$CALA .58 w/ $3 price upgrade out by Leerink

Eagle1

Eagle1 3 years ago

crudeoil24

crudeoil24 3 years ago

Company discontinued its KEAPSAKE clinical trial.

Eagle1

Eagle1 3 years ago

Hi why the drop here?

0210

0210 3 years ago

Calithera Biosciences CALA Q3 EPS $(0.15) Beats $(0.23) Estimate, Sales $6.75M, and a 53.13 percent increase over losses of $(0.32) per share from the same period last year.

4:42 pm ET November 9, 2021 (Benzinga)
Calithera Biosciences (NASDAQ:CALA) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 53.13 percent increase over losses of $(0.32) per share from the same period last year. The company reported $6.75 million in sales this quarter.

0210

0210 3 years ago

right-on-the-money...-54% to $0.86-0.87, from $1.90 on 21x dmav (of only 1,082,848 daily moving average volume).

SOURCE: https://ih.advfn.com/stock-market/NASDAQ/calithera-biosciences-CALA/historical

willlbone

willlbone 3 years ago

Bid at 60% drop.

TheFinalCD

TheFinalCD 3 years ago

$CALA -40%

Calithera Biosciences, Inc. | Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial

https://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-announces-decision-discontinue-keapsake

Elgordo84

Elgordo84 4 years ago

I’m expecting earnings to be on the up tomorrow
Let’s go $CALA

Elgordo84

Elgordo84 4 years ago

Looks like no one is paying attention
$CALA I guess is you and me!!!
Perfect for the run
While no one is watching.......

Elgordo84

Elgordo84 4 years ago

Ok hello $CALA
I LIKE WHAT I SEE HERE!!!!
Let’s take this for a ride...
$CALA LETS GO —————>

trade-stock000

trade-stock000 4 years ago

Cala when is the data due date? Thx

oaps222

oaps222 4 years ago

Thanks for the info.
Geez~~, what a move. I wish I knew it last Thursday! LOL

In any event, congratulations, if you already got in ARTL!

trade-stock000

trade-stock000 4 years ago

A-R-T-L is the one to watch (: PT $8-10
Add on correction price, read few post over there abt data and cocrystal CBD molecules. Apart from that it's focused on Lipid therapy the next frontier in Oncology.

oaps222

oaps222 4 years ago

Very good point, but be careful. The market is crazy. I can see some (big?) corrections in the near future.

oaps222

oaps222 4 years ago

From the recent 13G Filings, Adage Capital has reported its 4,000,000 shares of CALA (5.67% ownership) on Jan 13, 2021.

trade-stock000

trade-stock000 4 years ago

Yeah but in Jan that was not much of an update, that´s why stock plummeted, company needs more time.

Jan option price rose becoz of that reason, now fade out. Will visit this ticker later, for now it´s waste of cash esp when whole market is running nut

oaps222

oaps222 4 years ago

Was it on Jan 15-17, not Feb 15-17?
http://www.calithera.com/wp-content/uploads/2021/01/Arginase-1158-203-Poster.pdf

trade-stock000

trade-stock000 4 years ago

IV surges in the event of future price move. $5 call for Feb 19 it seems someone very bullish abt this stock and bot calls. Article u cited it's from Jan-13th, today its 13th Feb (:, unless next week something comes out which is highly unlikely.

oaps222

oaps222 4 years ago

I was doing a DD on CALA and found the following. I don't quite understand it. Can you share your thoughts on this?
"Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options"

https://finance.yahoo.com/news/implied-volatility-surging-calithera-biosciences-134001483.html

trade-stock000

trade-stock000 4 years ago

2.42 or lower test first before go up i hope

trade-stock000

trade-stock000 4 years ago

CALA on Feb 15-17 presenting Biliary-Tract Cancer-Data-could do-vroomvroom

jondoeuk

jondoeuk 4 years ago

ASH abstract https://ash.confex.com/ash/2020/webprogram/Paper137266.html

ClayTrader

ClayTrader 5 years ago

* * $CALA Video Chart 12-23-2019 * *

Link to Video - click here to watch the technical chart video

cashbyers

cashbyers 5 years ago

9.5M block trade today @ $4.45.. 17% stake or $42M investment...

ClayTrader

ClayTrader 5 years ago

* * $CALA Video Chart 11-19-19 * *

Link to Video - click here to watch the technical chart video

jonny_red

jonny_red 5 years ago

4 Penny Stocks To Watch In November After Latest Milestones

$GTBP $CALA $AVDL $BLCM

https://www.transparenttraders.me/2019/11/4-penny-stocks-to-watch-in-november.html

cashbyers

cashbyers 5 years ago

Long CALA @ $2.60

buypumps

buypumps 5 years ago

Conference call Monday also. Could push to 3.90 area.

Zmill

Zmill 5 years ago

TA of CALA https://msmoneymoves.com/2019/07/12/calithera-initiates-potential-buying-opportunity/

CashBowski

CashBowski 5 years ago

CALA going to close the gap today.

Zmill

Zmill 5 years ago

Research mentioning CALA https://wordpress.com/block-editor/post/msmoneymoves.com/11262

Calithera Biosciences

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions